Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Part of paid clinical trials in Dothan, Alabama.
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study ID
- NCT06372964
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Bipolar Depression
Eligibility Criteria
- Sex
- ALL
- Age
- 10 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Lumateperone — DRUGLumateperone administered orally, once daily.
- Placebo — DRUGMatching placebo administered orally, once daily.
Study Details
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Key Dates
- First listed
- Apr 18, 2024
- Start date
- May 14, 2024
- Status verified
- Jul 2026
- Primary completion
- Oct 31, 2031
- Completion
- Oct 31, 2031
Study Design
- Enrollment
- 384 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: LumateperoneLumateperone 42 mg for patient ages 13-17 years and Lumateperone 21 mg for patient ages 10-12 years.
- Placebo Comparator: PlaceboMatching placebo
Primary Outcome Measure
Children's Depression Rating Scale-Revised (CDRS-R) [ Time Frame: Week 6 ]
Central Contacts
- Study Contact844-434-4210
Locations (56)
Find similar trials in Dothan, AL
Related Studies
- Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar DepressionPHASE1/PHASE2 · Recruiting · Laureate Institute for Brain Research, Inc. · Tulsa, Oklahoma
- Deep Brain Stimulation of Treatment-Resistant Bipolar DepressionRecruiting · Wayne Goodman MD · Houston, Texas
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)PHASE3 · Recruiting · Xenon Pharmaceuticals Inc. · Tucson, Arizona
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)PHASE3 · Enrolling By Invitation · Xenon Pharmaceuticals Inc. · Little Rock, Arkansas